1Oncology Department, Hammoud Hospital UMC.
2Radiology Department, Hammoud Hospital UMC, Saida.
3Oncology Department, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University.
4Oncology Department, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
5Oncology Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles, Bruxelles, Belgium.
CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.